Company Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977022039

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:00:00 13/03/2026 GMT			5-day change	1st Jan Change
3.910 ^USD	-3.46%		-9.07%	-28.49%

03-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-22	Alert wrongly tagged to Bolt Biotherapeutics Inc withdrawn	RE

Business description: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. It developed a lead agonist antibody that binds to Dectin-2 and activates human tumor-associated macrophages. It is developing multiple Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Number of employees: 40

Sales by Activity: Bolt Biotherapeutics, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Biotechnology (Startups)	1.26M	5.73M	7.88M	7.69M	-

See all business segments

Geographical breakdown of sales: Bolt Biotherapeutics, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United States	1.26M	5.73M	7.88M	7.69M	-

See all geographic segments

Executive Committee: Bolt Biotherapeutics, Inc.

Manager	Title	Age	Since
William Quinn CEO	Chief Executive Officer	54	14/05/2024
Grant Yonehiro COO	Chief Operating Officer	61	14/05/2024
Sarah Nemec AUD	Comptroller/Controller/Auditor	50	14/05/2024
Wesley Burwell HRO	Human Resources Officer	-	31/12/2020

See BOLT BIOTHERAPEUTICS, INC. governance

Composition of the Board of Directors: Bolt Biotherapeutics, Inc.

Director	Title	Age	Since
Kathy LaPorte BRD	Director/Board Member	64	30/11/2020
William Quinn BRD	Director/Board Member	54	14/05/2024
Brian O'Callaghan CHM	Chairman	55	03/09/2024
Nicole Onetto BRD	Director/Board Member	72	13/12/2021
Laura Berner BRD	Director/Board Member	50	13/12/2022
Jakob Dupont BRD	Director/Board Member	61	02/09/2024

Composition of the Board of Directors

Shareholders: Bolt Biotherapeutics, Inc.

Name	Equities	%	Valuation
Sofinnova Investments, Inc. 7.175 %	137,721	7.175 %	622 499 $
Pivotal Bioventure Partners Investment Advisor LLC 4.558 %	87,486	4.558 %	395 437 $
Vivo Capital LLC 3.773 %	72,414	3.773 %	327 311 $
Renaissance Technologies LLC 2.867 %	55,025	2.867 %	248 713 $
T3 Companies LLC 1.98 %	38,000	1.98 %	171 760 $

List of BOLT BIOTHERAPEUTICS, INC. shareholders

Company details: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc.

900 Chesapeake Drive

94063, Redwood City

+650 665 9295

http://www.boltbio.com

address Bolt Biotherapeutics, Inc.(BOLT)

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BOLT BIOTHERAPEUTICS, INC.	-3.46%	-9.07%	-53.31%	-86.04%	7.51M
ARGENX SE	-0.36%	-1.35%	+14.77%	+88.22%	42.98B
WUXI APPTEC CO., LTD.	-1.13%	-2.60%	+48.72%	+15.07%	39.24B
INSMED INCORPORATED	-0.01%	-0.45%	+85.83%	+661.46%	30.07B
BIONTECH SE	+1.21%	-10.16%	-6.44%	-29.73%	21.88B
WUXI BIOLOGICS (CAYMAN) INC.	-1.71%	-5.01%	+48.15%	-31.24%	18.25B
GENMAB A/S	-2.18%	-1.50%	+24.54%	-31.71%	16.03B
AKESO, INC.	-0.81%	+2.70%	+55.65%	+177.93%	12.97B
SUMMIT THERAPEUTICS INC.	+4.27%	+6.68%	-16.00%	+953.59%	12.5B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.75%	+2.23%	+65.88%	-	11.76B
Average	-0.24%	-1.62%	+26.78%	+190.84%	20.57B
Weighted average by Cap.	-0.18%	-1.33%	+36.73%	+189.62%